Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

CMOs Cringe as GlaxoSmithKline Will be Cutting Its Use by 25%

GlaxoSmithKline provided information about its second-quarter financials this week. The attention focused on plans to kill more than 30 preclinical and clinical programs and allocate 80 percent of its research-and-development budget to respiratory and HIV/infectious diseases. But a closer look at new CEO Emma Walmsley’s plans point to big changes in the company’s manufacturing network as well.

Read More »

Boston Scientific Warns of Fluke Death Involving Its S-ICD Pacemaker

Boston Scientific called a single pacemaker-related death for its S-ICD implant a “fluke” that was the result of radiation corruption that negatively impacted the device’s memory.

Read More »

U.S. House panel spotlights use of FDA rules to slow generic drugs

Republican and Democratic lawmakers discussed ways to prevent drugmakers from using rules developed to safeguard patients to instead block the sale of cheaper medicines.

Read More »

Amgen gets fast FDA review for adding heart benefits to cholesterol drug label

Amgen Inc. said the U.S. FDA granted priority review to the company’s request to add important heart safety data to the label of its expensive injectable cholesterol drug Repatha.

Read More »

U.S. Senator expands opioid probe to distributors, drugmakers

U.S. Democratic Senator Claire McCaskill expanded an investigation into the causes of the opioid crisis plaguing the country, seeking information from four more drugmakers and three drug distributors.

Read More »

Bristol-Myers shares slump after rival’s failed study

Bristol-Myers Squibb shares fell as a failed cancer-drug trial at AstraZeneca could have negative implications for its similar immunotherapy treatment regimen.

Read More »

Scientists find sunscreen potential in Antarctic plants

Scientists in Chile have discovered molecules in two species of Antarctic flowers that protect the plants from solar radiation and could potentially be used in products such as sunscreen for humans and protection for vulnerable crops.

Read More »

Not-Yet Sold Tesaro Bags $340 Million Cancer Deal With Pharma Giant Takeda

There is a ray of sunshine for beleaguered Tesaro as Japanese pharma giant Takeda Pharmaceutical struck a deal worth up to $340 million for Asian development and marketing rights for recently approved PARP inhibitor Zejula (niraparib).

Read More »

Astellas Takes a $387 Million+ Loss as It Shuts Down SoCal’s Agensys

Astellas Pharma announced that the company is wrapping up its research operations with Santa Monica, Calif.-based Agenus.

Read More »

Alexion Redefines R&D Strategy, Discontinues Programs and Kills Deals With Moderna, Blueprint and Arbutus Biopharma

While reporting strong earnings, New Haven, Conn.-based Alexion Pharmaceuticals also indicated the company plans to retool its research-and-development strategy.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!


Ad Right Bottom